Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

Pfizer Completes £2.4 Billion Sale of Remaining Haleon Stake

The pharmaceutical giant's exit solidifies Haleon's independence and positions BlackRock as its largest shareholder.

Haleon has been called a success story by some in the City at a difficult time for the wider London capital markets
Brian Mcnamara, Haleon chief executive, said the company was well placed to capitalise on the significant opportunities ahead

Overview

  • Pfizer has sold its final 7% stake in Haleon for £2.4 billion, fully exiting the consumer healthcare company.
  • Haleon repurchased 44 million shares from Pfizer for £170 million as part of its £500 million share buyback program.
  • BlackRock Investment Management has become Haleon's largest shareholder, holding more than 5% of the company.
  • Since its demerger from GSK in 2022, Haleon has focused on debt reduction, portfolio refinement, and shareholder returns.
  • Haleon's share price has recovered above its initial demerger valuation, reflecting improved investor confidence.